注射用灯盏花素治疗糖尿病周围神经病变45例

石雨时; 袁艺; 李如星; 吕仲琴; 张平

doi:10.11653/syfj2013230274

您当前的位置：

首页 >

文章列表页 >

注射用灯盏花素治疗糖尿病周围神经病变45例

更新时间：2024-01-04

- 注射用灯盏花素治疗糖尿病周围神经病变45例
- Breviscapine Injection the Treatment of Diabetic Peripheral Neuropathy of 45 Cases
- 中国实验方剂学杂志 2013年19卷第23期页码：274-277
- 作者机构：
- 作者简介：
- 基金信息：
  
  四川省中医药管理局项目(20101075Z-1)
- DOI：10.11653/syfj2013230274
  中图分类号：
- 纸质出版日期：2013
- 稿件说明：
移动端阅览
石雨时, 袁艺, 李如星, 等. 注射用灯盏花素治疗糖尿病周围神经病变45例[J]. 中国实验方剂学杂志, 2013,19(23):274-277.

SHI Yu-shi, YUAN Yi, LI Ru-xing, et al. Breviscapine Injection the Treatment of Diabetic Peripheral Neuropathy of 45 Cases[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(23): 274-277.
石雨时, 袁艺, 李如星, 等. 注射用灯盏花素治疗糖尿病周围神经病变45例[J]. 中国实验方剂学杂志, 2013,19(23):274-277. DOI： 10.11653/syfj2013230274.

SHI Yu-shi, YUAN Yi, LI Ru-xing, et al. Breviscapine Injection the Treatment of Diabetic Peripheral Neuropathy of 45 Cases[J]. Chinese journal of experimental traditional medical formulae, 2013, 19(23): 274-277. DOI： 10.11653/syfj2013230274.

摘要

目的: 探讨注射用灯盏花素对糖尿病周围神经病变（DPN）患者神经功能和氧化应激的影响。方法: 90例DPN患者随机按数字法分为观察组和对照组各45例。对照组采用甲钴胺片0.5 mg/次，3次/d。疗程12周。观察组在对照组基础上加用注射用灯盏花素50 mg，1次/d，2周为1个疗程，间隔2周后进行下一疗程，共3个疗程。记录治疗前后神经症状、体征评分，检测治疗前后正中神经、尺神经、腓总神经、胫前神经的运动传导速度（MNCV）和感觉传导速度（SNCV），检测血清总抗氧化能力（TAOC）、超氧化物歧化酶（SOD）、丙二醛（MDA）。结果: 观察组总有效率91.11%，优于对照组的71.11%（P<0.05）;治疗后两组神经症状、体征评分及总分均较治疗前显著下降，观察组评分低于对照组（P<0.01）;治疗后两组正中神经、尺神经、腓总神经、胫前神经的MNCV均有明显改善，观察组的改善优于对照组（P<0.05或P<0.01）;治疗后两组正中神经、尺神经、腓总神经、胫前神经的SNCV均有明显改善，观察组的改善优于对照组（P<0.01）;治疗后观察组TAOC、SOD水平较治疗前升高，并高于对照组（P<0.05），MDA水平显著下降，并低于对照组（P<0.01）。结论: 注射用灯盏花素能改善DPN患者神经症状、体征，改善神经运动神经传导速度和感觉传导速度，疗效显著，其作用机制可能与减轻氧化应激损伤有关。

Abstract

Objective: Breviscapine injection To observe the influence on nerve function and oxidative stress of patients with diabetic peripheral neuropathy disease. Method: Ninety patients were randomly divided into observation group (n=45) and control group (n=45).Patients in the control group were treated with conventional Western therapy. Patients in observation group were treated with mecobalamine tablets

0.5 mg/time

3 times/d

12 weeks as on cycle. Breviscapine injection was added to the patients in observation group

50 mg

1 times/d

2 weeks for one cycle

interval of two weeks after the next course of treatment. Recorded neurological symptoms and signs scores before and after treatment

detected conduction velocity (MNCV) and sensory conduction velocity (SNCV) of the median nerve

ulnar nerve

peroneal nerve

tibial nerve

and detected serum total antioxidant capacity (TAOC)

superoxide dismutase (SOD)

malondialdehyde (MDA) before and after the treatment. Result: The total efficacy of the observation group (91.11% ) was significantly better than the control group (71.11% )(P<0.05). After treatment

neurological symptoms

signs score and total score were decreased significantly

and the score of observation group was lower than the control group(P<0.01). MNCV of median nerve

ulnar nerve

peroneal nerve

tibial nerve showed significant improvement

the improvement of the observation group was better than the control group (P<0.05 or P<0.01);SNCV of median nerve

ulnar nerve

peroneal nerve

tibial nerve showed significant improvement

the improvement of the observation group was better than the control group (P<0.01);After treatment

TAOC

SOD levels of the observation group were raised and was higher than the control group (P<0.05)

MDA levels were significantly decreased

and lower than the control group (P<0.01). Conclusion: Breviscapine injection can improve the patients with DPN on neurological symptoms and signs

and can improve nerve motor nerve conduction velocity and sensory conduction velocity.Curative effect is distinct and its mechanism may reduce oxidative stress injury.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

p38 MAPK通路在糖尿病周围神经病变中的作用及中药干预的研究进展

从氧化应激角度探讨补阳还五汤对糖尿病周围神经病变大鼠的治疗作用

补肾通络方对糖尿病周围神经病变氧化应激影响

糖尿病周围神经病变中医临床及实验研究近况